Bolt Biotherapeutics (NASDAQ:BOLT) Stock Passes Below 200 Day Moving Average – Here’s What Happened

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)’s share price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $5.09 and traded as low as $4.62. Bolt Biotherapeutics shares last traded at $4.6830, with a volume of 4,843 shares trading hands.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Monday, April 20th. Rodman & Renshaw assumed coverage on Bolt Biotherapeutics in a research note on Thursday, May 28th. They set a “buy” rating and a $22.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Bolt Biotherapeutics currently has a consensus rating of “Hold” and a consensus target price of $34.67.

Bolt Biotherapeutics Stock Up 7.7%

The company has a quick ratio of 3.51, a current ratio of 3.51 and a debt-to-equity ratio of 0.98. The stock has a market cap of $9.16 million, a PE ratio of -0.29 and a beta of 1.12. The business has a 50 day moving average price of $4.80 and a 200 day moving average price of $5.09.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its earnings results on Tuesday, May 12th. The company reported ($4.31) EPS for the quarter, missing analysts’ consensus estimates of ($2.85) by ($1.46). Bolt Biotherapeutics had a negative return on equity of 100.89% and a negative net margin of 455.15%.The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $1.50 million. Equities research analysts expect that Bolt Biotherapeutics, Inc. will post -11.1 EPS for the current fiscal year.

Institutional Trading of Bolt Biotherapeutics

A number of hedge funds have recently modified their holdings of BOLT. Squarepoint Ops LLC boosted its stake in shares of Bolt Biotherapeutics by 19.8% in the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after buying an additional 2,448 shares during the last quarter. Shay Capital LLC purchased a new stake in shares of Bolt Biotherapeutics in the third quarter worth about $85,000. Susquehanna International Group LLP purchased a new stake in shares of Bolt Biotherapeutics in the third quarter worth about $89,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Bolt Biotherapeutics in the fourth quarter worth about $112,000. Finally, T3 Companies LLC purchased a new stake in shares of Bolt Biotherapeutics in the fourth quarter worth about $208,000. Hedge funds and other institutional investors own 86.70% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.